Abstract
BackgroundGranulocyte colony-stimulating factor (G-CSF) is a pharmacologic agent inducing neutrophil mobilization and a new candidate for neuroprotection and neuroregeneration in stroke. Its effects when used in combination with tissue plasminogen activator (tPA) were explored during the acute phase of ischemic stroke.MethodsWe used a middle cerebral artery occlusion (MCAO) model of cerebral ischemia, associated with treatment with tPA, in male spontaneously hypertensive rats (SHR). Granulocyte colony-stimulating factor (G-CSF; 60 μg/kg) was injected just before tPA. Neutrophil response in peripheral blood and in the infarct area was quantified in parallel to the infarct volume. Protease matrix metallopeptidase 9 (MMP-9) release from circulating neutrophils was analyzed by immunochemistry and zymography. Vascular reactivity and hemorrhagic volume in the infarct area was also assessed.ResultsTwenty four hours after ischemia and tPA, G-CSF administration induced a significant increase of neutrophils in peripheral blood (P <0.05). At 72 hours post-ischemia, G-CSF was significantly associated with an increased risk of hemorrhage in the infarct area (2.5 times more likely; P <0.05) and significant cerebral endothelium-dependent dysfunction. Ex vivo, an increased MMP-9 release from neutrophils after tPA administration correlated to the increased hemorrhagic risk (P <0.05). In parallel, G-CSF administration was associated with a decreased neutrophil infiltration in the infarct area (-50%; P <0.05), with a concomitant significant neuroprotective effect (infarct volume: -40%; P <0.05).ConclusionsWe demonstrate that G-CSF potentiates the risk of hemorrhage in experimental stroke when used in combination with tPA by inducing neutrophilia. This effect is concomitant to an increased MMP-9 release from peripheral neutrophils induced by the tPA treatment. These results highlight the potential hemorrhagic risk of associating G-CSF to thrombolysis during the acute phase of stroke.
Highlights
Granulocyte colony stimulating factor (G-CSF) is a hematopoietic cytokine initially used in the treatment of neutropenia for its effects on proliferation and maturation of the granulocyte cell line.Recently, Granulocyte colony-stimulating factor (G-CSF) displayed a neuroprotective effect when used during experimental stroke by both decreasing the infarct size and improving motor function recovery [1,2,3]
Given the role played by polymorphonuclear neutrophils (PMN) in the physiopathology of these post-tissue plasminogen activator (tPA) hemorrhagic complications [6], the objective of this work was to analyze the impact of G-CSF on the risk of hemorrhage when used in combination with tPA during the acute phase of an experimental ischemic stroke
There were no differences in physiologic parameters between the control and G-CSF administered groups before, during, and after the surgical procedure
Summary
G-CSF displayed a neuroprotective effect when used during experimental stroke by both decreasing the infarct size and improving motor function recovery [1,2,3]. At the acute phase of ischemic stroke, the question of combining G-CSF with tissue plasminogen activator (tPA), used for thrombolysis, is raised. Given the role played by polymorphonuclear neutrophils (PMN) in the physiopathology of these post-tPA hemorrhagic complications [6], the objective of this work was to analyze the impact of G-CSF on the risk of hemorrhage when used in combination with tPA during the acute phase of an experimental ischemic stroke. Granulocyte colony-stimulating factor (G-CSF) is a pharmacologic agent inducing neutrophil mobilization and a new candidate for neuroprotection and neuroregeneration in stroke. Its effects when used in combination with tissue plasminogen activator (tPA) were explored during the acute phase of ischemic stroke
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
